REQUEST A DEMO
Total
USD $0.00
Search more companies

Hansoh Pharmaceutical Group Company Limited (Hong Kong) (Hong Kong SAR, China)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Hansoh Pharmaceutical Group Company Limited Profile Updated: July 27, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

The Company is a China-based investment holding was incorporated in the Cayman Islands under the Companies Law as an exempted company with limited liability on 2 December 2015. On 14 June 2019, the Company has listed at MAIN Board of Hong Kong Stock Exchange.
The Company and its subsidiaries are principally engaged in the research and development, production and sale of pharmaceutical products in China. The Company's main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company's products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market. The company has over 20 years of R D experience, as evidenced by top-two ranking as of June 30, 2018 in both the number of Category 1.1 innovative drug candidates with IND approval and the number of first-to-market generic drug approvals since 2011. The company has began development of Category 1.1 innovative drugs in 2002. They have become Chinese pharmaceutical companies that have successfully developed and marketed two Category 1.1 innovative drugs with NMEs, including pipeline Category 1.1 innovative drug polyethylene glycol loxenatide, launched in May 2019.
MILESTONES :

1995 - Jiangsu Hansoh as major operating subsidiary was established in China.
2000 - First GMP manufacturing facility in Lianyungang, Jiangsu Province is launched and commenced production of solid oral formulations.
2002 - The company were recognized as a Key High and New-Technology Enterprise of the National Torch Program. The company obtained Chinese GMP certifications for our production of large volume parenteral solutions.
2003 - Active pharmaceutical ingredient, vinorelbine tartrate, was approved by the U.S. FDA.
2006 - The company was received approval to establish a Postdoctoral Program Workstation by the Ministry of Personnel and the National Postdoctoral Management Committee of China.
2008 - The company was certified as a National Enterprise Technology Center.
2014 - Self-developed Category 1.1 innovative drug Mailingda (morinidazole sodium chlorider injection), the latest generation nitroimidazole-class antibiotic, was approved for sale in China.
2015 - core product, Zefei (gemcitabine hydrochloride for injection), was recognized as a Famous China Trademark y the Trademark Office of the State Administration for Industry Commerce of China.
2016 - Hillhouse was brought in as investor. core product, Oulanning (olanzapine tablets), received the China Patent Excellence Award from the State Intellectual Property Office of China. core product, Xinwei (imatinib mesylate tablets), received the first prize for the
Advancement of Science and Technology by the All-China Federation of Industry Commerce. core product, Pulaile (pemetrexed disodium for injection), was approved by the PMDA.

Headquarters
9 Dongjin Road, Economic Technical Development Zone, Lianyungang
Lianyungang; Jiangsu; Postal Code: 222069

Contact Details: Purchase the Hansoh Pharmaceutical Group Company Limited (Hong Kong) report to view the information.

Website: http://www.hspharm.com

Basic Information
Total Employees:
Purchase the Hansoh Pharmaceutical Group Company Limited (Hong Kong) report to view the information.
Outstanding Shares:
Purchase the Hansoh Pharmaceutical Group Company Limited (Hong Kong) report to view the information.
Registered Capital:
Purchase the Hansoh Pharmaceutical Group Company Limited (Hong Kong) report to view the information.
Financial Auditors:
Purchase the Hansoh Pharmaceutical Group Company Limited (Hong Kong) report to view the information.
Incorporation Date:
2015
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
65.73%
Purchase this report to view the information.
16.01%
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Changzhou Hengbang Pharmaceutical Co., Ltd. ('Changzhou Hengbang') (China)
100%
Hansoh (Shanghai) Health Technology Co., Ltd. (China)
100%
Hansoh Investment Co., Ltd. ('Hansoh Investment') (China)
100%
Company Performance
Financial values in the chart are available after Hansoh Pharmaceutical Group Company Limited (Hong Kong) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
44.21%
Total operating revenue
43.54%
Operating profit (EBIT)
138.98%
EBITDA
128.22%
Net Profit (Loss) for the Period
111.47%
Total assets
-0.84%
Total equity
15.42%
Operating Profit Margin (ROS)
15.84%
Net Profit Margin
13.33%
Return on Equity (ROE)
4.44%
Debt to Equity Ratio
-18.61%
Quick Ratio
4.15%
Cash Ratio
1.39%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?